Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

2.

Reversal agents for NOACs: Connecting the dots.

Dalal J, Bhave A, Chaudhry G, Rana P.

Indian Heart J. 2016 Jul-Aug;68(4):559-63. doi: 10.1016/j.ihj.2015.11.023. Review.

3.

Can We Predict Individual Combined Benefit and Harm of Therapy? Warfarin Therapy for Atrial Fibrillation as a Test Case.

Li G, Thabane L, Delate T, Witt DM, Levine MA, Cheng J, Holbrook A.

PLoS One. 2016 Aug 11;11(8):e0160713. doi: 10.1371/journal.pone.0160713.

4.

Effect of vitamin K2 on the anticoagulant activity of warfarin during the perioperative period of catheter ablation: Population analysis of retrospective clinical data.

Zhou Z, Yano I, Odaka S, Morita Y, Shizuta S, Hayano M, Kimura T, Akaike A, Inui K, Matsubara K.

J Pharm Health Care Sci. 2016 Aug 4;2:17. doi: 10.1186/s40780-016-0053-8.

5.

Quality of anticoagulation therapy in neurological patients in a tertiary care hospital in north India.

Singh P, Kalita J, Misra UK.

Indian J Med Res. 2016 Apr;143(4):428-33. doi: 10.4103/0971-5916.184301.

6.

Role of anticoagulation in neurological practice.

Verma R.

Indian J Med Res. 2016 Apr;143(4):392-4. doi: 10.4103/0971-5916.184279. No abstract available.

7.

Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses.

Li X, Tse VC, Lau WC, Cheung BM, Lip GY, Wong IC, Chan EW.

PLoS One. 2016 Jun 30;11(6):e0157129. doi: 10.1371/journal.pone.0157129.

8.

Crystal structures of 4-methyl-2-oxo-2H-chromene-7,8-diyl di-acetate and 4-methyl-2-oxo-2H-chromene-7,8-diyl bis-(pent-4-ynoate).

Akinyemi A, Thomas C, Marsh W, Butcher RJ, Jasinski JP, Maynard-Smith LA.

Acta Crystallogr E Crystallogr Commun. 2016 Apr 15;72(Pt 5):704-8. doi: 10.1107/S2056989016005892.

9.

New anticoagulants for the treatment of venous thromboembolism.

Fernandes CJ, Alves JĂșnior JL, Gavilanes F, Prada LF, Morinaga LK, Souza R.

J Bras Pneumol. 2016 Apr;42(2):146-54. doi: 10.1590/S1806-37562016042020068. English, Portuguese.

10.

Warfarin-induced raised international normalized ratio is further prolonged by pantoprazole.

Chandelia S, Dubey NK.

Indian J Crit Care Med. 2016 Feb;20(2):127-8. doi: 10.4103/0972-5229.175934. No abstract available.

11.

Evaluation of knowledge of Health care professionals on warfarin interactions with drug and herb medicinal in Central Saudi Arabia.

Al-Arifi MN, Wajid S, Al-Manie NK, Al-Saker FM, Babelgaith SD, Asiri YA, Sales I.

Pak J Med Sci. 2016 Jan-Feb;32(1):229-33. doi: 10.12669/pjms.321.8902.

12.

Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients.

Cho SM, Lee KY, Choi JR, Lee KA.

Yonsei Med J. 2016 May;57(3):635-40. doi: 10.3349/ymj.2016.57.3.635.

13.

Interaction Between Dietary Vitamin K Intake and Anticoagulation by Vitamin K Antagonists: Is It Really True?: A Systematic Review.

Violi F, Lip GY, Pignatelli P, Pastori D.

Medicine (Baltimore). 2016 Mar;95(10):e2895. doi: 10.1097/MD.0000000000002895.

14.

Is the HAS-BLED score useful in predicting post-extraction bleeding in patients taking warfarin? A retrospective cohort study.

Kataoka T, Hoshi K, Ando T.

BMJ Open. 2016 Mar 2;6(3):e010471. doi: 10.1136/bmjopen-2015-010471.

15.

Bleeding associated with coadministration of rivaroxaban and clarithromycin.

Fralick M, Juurlink DN, Marras T.

CMAJ. 2016 Jun 14;188(9):669-72. doi: 10.1503/cmaj.150580. No abstract available.

PMID:
26811362
16.

Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism.

Witt DM, Clark NP, Kaatz S, Schnurr T, Ansell JE.

J Thromb Thrombolysis. 2016 Jan;41(1):187-205. doi: 10.1007/s11239-015-1319-y. Review.

17.

The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants.

Dalal J, Bhave A, Oomman A, Vora A, Saxena A, Kahali D, Poncha F, Gambhir DS, Chaudhuri JR, Sinha N, Ray S, Iyengar SS, Banerjee S, Kaul U; SPAF Academy India experts..

Indian Heart J. 2015 Dec;67 Suppl 2:S13-34. doi: 10.1016/j.ihj.2015.10.380.

18.

Pharmacogenetics-Based versus Conventional Dosing of Warfarin: A Meta-Analysis of Randomized Controlled Trials.

Shi C, Yan W, Wang G, Wang F, Li Q, Lin N.

PLoS One. 2015 Dec 16;10(12):e0144511. doi: 10.1371/journal.pone.0144511.

19.

Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis.

Romley JA, Gong C, Jena AB, Goldman DP, Williams B, Peters A.

BMJ. 2015 Dec 7;351:h6223. doi: 10.1136/bmj.h6223.

20.

Prediction of individual combined benefit and harm for patients with atrial fibrillation considering warfarin therapy: a study protocol.

Li G, Holbrook A, Delate T, Witt DM, Levine MA, Thabane L.

BMJ Open. 2015 Nov 5;5(11):e009518. doi: 10.1136/bmjopen-2015-009518.

Items per page

Supplemental Content

Support Center